Skip to content

OS Therapies OSTX TEDCO Grant Non Current

TEDCO Grant Non Current at other companies

Shenandoah Telecom logo
Shenandoah TelecomSHEN
$11.55M+66.7%
CBAK Energy Technology, Inc. logo
CBAK Energy Technology, Inc.CBAT
$10.2M-0.7%
VAN
Vivani MedicalVANI
$0
Espey Manufacturing & Electronics Corp. logo
Espey Manufacturing & Electronics Corp.ESP
$1.01M+24.5%
TuHURA Biosciences, Inc. logo
TuHURA Biosciences, Inc.HURA
$0-100%
Alpha Cognition logo
Alpha CognitionACOG
$174.68K-3.0%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept osti:TEDCOGrantNonCurrent.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's tedco grant non current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's TEDCO grant non current?
OS Therapies (OSTX) reported TEDCO grant non current of $100K in Q1 2026.
How has OS Therapies's TEDCO grant non current changed year-over-year?
OS Therapies's TEDCO grant non current decreased by 0.0% year-over-year, from $100K to $100K.
What is the long-term trend for OS Therapies's TEDCO grant non current?
Over 2 years (2023 to 2025), OS Therapies's TEDCO grant non current has grown at a 0.0% compound annual growth rate (CAGR), from $100K to $100K.
What does TEDCO grant non current mean?
This reflects long-term funding received through government or institutional grants that is subject to specific performance or time-based restrictions. It represents non-dilutive capital that supports research and development initiatives beyond the current fiscal year.